

# Ming-Sound Tsao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6779123/publications.pdf>

Version: 2024-02-01

556  
papers

61,334  
citations

2098

100  
h-index

1089

232  
g-index

565  
all docs

565  
docs citations

565  
times ranked

63459  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 277-288.	0.5	11
2	The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. <i>Journal of Thoracic Oncology</i> , 2022, 17, 608-622.	0.5	64
3	Introduction to 2021 WHO Classification of Thoracic Tumors. <i>Journal of Thoracic Oncology</i> , 2022, 17, e1-e4.	0.5	19
4	Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100259.	0.6	1
5	Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1966-1978.	3.2	11
6	Reprint of "Introduction to 2021 WHO Classification of Thoracic Tumors". <i>Journal of Thoracic Oncology</i> , 2022, 17, 337-340.	0.5	3
7	Integrin $\alpha 11 \beta 21$ in tumor fibrosis: more than just another cancer-associated fibroblast biomarker?. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 649-660.	1.8	9
8	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. <i>Nature Communications</i> , 2022, 13, 1811.	5.8	21
9	Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 205.	1.7	10
10	Molecular testing and patterns of treatment in patients with NSCLC: An IASLC analysis of ASCO CancerLinQ Discovery Data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9128-9128.	0.8	1
11	Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4428-4437.	0.9	5
12	Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3039-3039.	0.8	0
13	Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. <i>Genetic Epidemiology</i> , 2021, 45, 99-114.	0.6	7
14	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	0.9	31
15	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 190-197.	5.1	34
16	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 826-838.	1.3	5
17	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
18	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. <i>Cell Reports</i> , 2021, 34, 108707.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection. <i>Immunity</i> , 2021, 54, 526-541.e7.	6.6	25
20	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. <i>Pathology</i> , 2021, 53, 446-453.	0.3	25
21	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
22	Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. <i>Scientific Reports</i> , 2021, 11, 10619.	1.6	15
23	Immune Resistance Interrogation Study (IRIS): A prospective comprehensive multi-omic analysis in patients with intrinsic and acquired resistance to immunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2679-TPS2679.	0.8	0
24	The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3126-3126.	0.8	0
25	Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis. <i>American Journal of Clinical Pathology</i> , 2021, 156, 989-999.	0.4	12
26	Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21123-e21123.	0.8	2
27	Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8547-8547.	0.8	1
28	Impact of <i>KRAS</i> mutational variant on response to immunotherapy in metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21127-e21127.	0.8	3
29	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. <i>Lung Cancer</i> , 2021, 156, 76-81.	0.9	7
30	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. <i>Journal of Thoracic Oncology</i> , 2021, 16, 897-901.	0.5	8
31	Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 253-259.	1.1	47
32	Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. <i>Cancer Cell</i> , 2021, 39, 1115-1134.e12.	7.7	86
33	Risk Perception Among a Lung Cancer Screening Population. <i>Chest</i> , 2021, 160, 718-730.	0.4	8
34	Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1798-1809.	0.5	61
35	Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System. <i>Current Oncology</i> , 2021, 28, 3268-3279.	0.9	12
36	Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1490-1500.	0.5	26

#	ARTICLE	IF	CITATIONS
37	Molecular testing in stage III non-small cell lung cancer: Approaches and challenges. <i>Lung Cancer</i> , 2021, 162, 42-53.	0.9	22
38	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 136-151.	0.9	40
39	Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. <i>Translational Oncology</i> , 2021, 14, 101179.	1.7	11
40	Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 127-135.	0.9	16
41	Stratification and management of patients ineligible for lung cancer screening. <i>Respiratory Medicine</i> , 2021, 188, 106610.	1.3	0
42	Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. <i>Journal of Molecular Biology</i> , 2021, 433, 167294.	2.0	4
43	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. <i>Nature Communications</i> , 2021, 12, 6274.	5.8	22
44	Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage 3 non-small cell lung cancer: safety and efficacy. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100251.	0.6	3
45	Assessing therapy response in patient-derived xenografts. <i>Science Translational Medicine</i> , 2021, 13, eabf4969.	5.8	5
46	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110563.	1.4	6
47	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 64-77.	1.9	30
48	Malignant mesothelioma in situ: morphologic features and clinical outcome. <i>Modern Pathology</i> , 2020, 33, 297-302.	2.9	79
49	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	2.9	135
50	Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2020, 39, 308-321.	2.6	15
51	A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 1077-1084.	1.2	15
52	Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. <i>Modern Pathology</i> , 2020, 33, 281-296.	2.9	33
53	Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1162-1174.	3.2	148
54	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106

#	ARTICLE	IF	CITATIONS
55	Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2082-2091.e1.	0.4	28
56	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 344-359.	0.5	87
57	Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. <i>Clinical Trials</i> , 2020, 17, 202-211.	0.7	2
58	PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry. <i>Lung Cancer</i> , 2020, 148, 55-61.	0.9	5
59	Point-of-Care Spirometry Identifies High-Risk Individuals Excluded from Lung Cancer Screening. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1473-1477.	2.5	1
60	Implementation of PD-L1 22C3 IHC pharmDx™;TM™; in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytolytA® Prefixation. <i>Acta Cytologica</i> , 2020, 64, 577-587.	0.7	14
61	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2214-2232.	1.3	51
62	Cover Image, Volume 40, Issue 6. <i>Medicinal Research Reviews</i> , 2020, 40, ii.	5.0	0
63	Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. <i>BMC Pulmonary Medicine</i> , 2020, 20, 300.	0.8	12
64	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	0.5	21
65	Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways. <i>Cancers</i> , 2020, 12, 2071.	1.7	34
66	Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 236-265.	0.2	9
67	Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor. <i>Scientific Reports</i> , 2020, 10, 14514.	1.6	31
68	Cancer proteome and metabolite changes linked to SHMT2. <i>PLoS ONE</i> , 2020, 15, e0237981.	1.1	18
69	Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. <i>Pharmaceuticals</i> , 2020, 13, 289.	1.7	8
70	Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12101-12108.	3.3	46
71	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. <i>JCO Precision Oncology</i> , 2020, 4, 520-533.	1.5	9
72	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020, 11, 2220.	5.8	31

#	ARTICLE	IF	CITATIONS
73	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020, 146, 78-85.	0.9	24
74	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020, 33, 1874-1888.	2.9	18
75	The role of FOXOs and autophagy in cancer and metastasis—implications in therapeutic development. <i>Medicinal Research Reviews</i> , 2020, 40, 2089-2113.	5.0	26
76	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020, 146, 350-354.	0.9	14
77	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
78	Recapitulating Pancreatic Tumor Microenvironment through Synergistic Use of Patient Organoids and Organ-on-a-Chip Vasculature. <i>Advanced Functional Materials</i> , 2020, 30, 2000545.	7.8	62
79	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1037-1053.	0.5	40
80	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3431-3442.	3.2	41
81	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	0.5	234
82	Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 276-284.	0.9	15
83	A drug discovery platform to identify compounds that inhibit EGFR triple mutants. <i>Nature Chemical Biology</i> , 2020, 16, 577-586.	3.9	30
84	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020, 143, 1-11.	0.9	19
85	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , 2020, 26, 2477-2486.	3.2	16
86	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020, 21, e488-e492.	1.1	5
87	Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1328-1337.	0.5	19
88	EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. <i>Lung Cancer</i> , 2020, 145, 144-151.	0.9	4
89	CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9502-9502.	0.8	23
90	Polarimetric second-harmonic generation microscopy of the hierarchical structure of collagen in stage I-III non-small cell lung carcinoma. <i>Biomedical Optics Express</i> , 2020, 11, 1851.	1.5	30

#	ARTICLE	IF	CITATIONS
91	Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, e21092-e21092.	0.8	0
92	Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2020, 38, e21080-e21080.	0.8	0
93	TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.. Journal of Clinical Oncology, 2020, 38, 3050-3050.	0.8	1
94	A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006).. Journal of Clinical Oncology, 2020, 38, TPS9079-TPS9079.	0.8	0
95	Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC.. Journal of Clinical Oncology, 2020, 38, 3084-3084.	0.8	0
96	Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers.. Journal of Clinical Oncology, 2020, 38, 3571-3571.	0.8	0
97	Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway. , 2020, , .		1
98	CD45+CD326+ Cells are Predictive of Poor Prognosis in Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2019, 25, 6756-6763.	3.2	11
99	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. Journal of Thoracic Oncology, 2019, 14, 1704-1717.	0.5	8
100	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing. Cancer, 2019, 125, 4043-4051.	2.0	14
101	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. Cancers, 2019, 11, 1009.	1.7	2
102	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1228-1237.	1.1	11
103	Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts. Journal of Thoracic Oncology, 2019, 14, 1003-1011.	0.5	11
104	Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method. The Lancet Digital Health, 2019, 1, e353-e362.	5.9	76
105	PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC. Scientific Reports, 2019, 9, 12437.	1.6	13
106	Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. BMJ Open, 2019, 9, e024719.	0.8	32
107	Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. , 2019, 7, 17.		38
108	Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 935-942.	1.1	21

#	ARTICLE	IF	CITATIONS
109	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019, 10, 278.	5.8	143
110	LOXL1 Is Regulated by Integrin $\alpha 11$ and Promotes Non-Small Cell Lung Cancer Tumorigenicity. <i>Cancers</i> , 2019, 11, 705.	1.7	49
111	Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. <i>Cancer Research</i> , 2019, 79, 4539-4550.	0.4	34
112	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 32-39.	0.9	14
113	Pulmonary Adenocarcinoma Pathology and Molecular Testing. , 2019, , 13-33.		1
114	Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 123.	3.5	32
115	Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion. <i>Neoplasia</i> , 2019, 21, 482-493.	2.3	30
116	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , 2019, 130, 135-142.	0.9	10
117	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 377-407.	0.5	212
118	Old Soldiers Never Die: Is There Still a Role for Immunohistochemistry in the Era of Next-Generation Sequencing Panel Testing?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2035-2038.	0.5	10
119	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 699-714.	0.6	36
120	Predicting Malignancy Risk of Screen-Detected Lung Nodules Mean Diameter or Volume. <i>Journal of Thoracic Oncology</i> , 2019, 14, 203-211.	0.5	34
121	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	0.5	68
122	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e338-e345.	1.1	14
123	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. <i>Nature Communications</i> , 2019, 10, 224.	5.8	66
124	Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. <i>Carcinogenesis</i> , 2019, 40, 432-440.	1.3	5
125	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006596.	1.5	51
126	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 66-73.e6.	1.1	19



#	ARTICLE	IF	CITATIONS
127	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the OncoPrint Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.. Journal of Clinical Oncology, 2019, 37, 2620-2620.	0.8	9
128	Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients.. Journal of Clinical Oncology, 2019, 37, e20091-e20091.	0.8	2
129	Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2019, 37, e20667-e20667.	0.8	1
130	Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung adenocarcinoma (LUAD).. Journal of Clinical Oncology, 2019, 37, 3110-3110.	0.8	0
131	Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.. Journal of Clinical Oncology, 2019, 37, e20594-e20594.	0.8	0
132	Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis.. Journal of Clinical Oncology, 2019, 37, e20574-e20574.	0.8	0
133	Abstract 3378: Systematic pharmacogenomic analysis of large patient derived xenografts data. , 2019, , .		0
134	Abstract 4550: Correlations between tumor mutation burden, inflammatory profile and histological characteristics of tumor microenvironment in early-stage squamous cell lung carcinoma. , 2019, , .		0
135	A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clinical Colorectal Cancer, 2018, 17, 231-239.e7.	1.0	42
136	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 323-358.	0.5	408
137	Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. Laboratory Investigation, 2018, 98, 403-413.	1.7	10
138	Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC). BMC Cancer, 2018, 18, 429.	1.1	4
139	The eighth TNM classification for lung cancer—What is next?. Lung Cancer, 2018, 121, 97-98.	0.9	2
140	Multiplexed Real-Time NMR GTPase Assay for Simultaneous Monitoring of Multiple Guanine Nucleotide Exchange Factor Activities from Human Cancer Cells and Organoids. Journal of the American Chemical Society, 2018, 140, 4473-4476.	6.6	9
141	Genomic Testing in Lung Cancer: Past, Present, and Future. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 323-334.	2.3	20
142	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 408-419.	1.2	70
143	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer, 2018, 17, 73-79.	1.0	17
144	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.		0

#	ARTICLE	IF	CITATIONS
145	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	0.8	223
146	Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes. <i>Oncotarget</i> , 2018, 9, 9137-9155.	0.8	13
147	Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. <i>Nature Communications</i> , 2018, 9, 3927.	5.8	43
148	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
149	Refined RIP-seq protocol for epitranscriptome analysis with low input materials. <i>PLoS Biology</i> , 2018, 16, e2006092.	2.6	112
150	Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway. <i>Nutrients</i> , 2018, 10, 1289.	1.7	27
151	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 416-427.	1.3	11
152	The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 22-29.	0.9	28
153	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	0.5	589
154	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. <i>Cell</i> , 2018, 174, 564-575.e18.	13.5	264
155	Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5990-6000.	3.2	17
156	Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIVOTAL observational study. <i>PLoS ONE</i> , 2018, 13, e0202865.	1.1	50
157	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. <i>Nature Communications</i> , 2018, 9, 3221.	5.8	60
158	Abstract 4360: Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer. , 2018, , .		14
159	A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CTG) Tj ETQq1 1 0.784314 rgBT /Overlook 10 Tf 50 177 Td		50
160	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018, 9, 22559-22570.	0.8	20
161	Upfront next generation sequencing in NSCLC: A publicly funded perspective.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12062-12062.	0.8	2
162	The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8533-8533.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Abstract 2443: Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma. , 2018, , .		0
164	ALK -Rearranged Non-“Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , 2017, 18, 156-161.	1.1	78
165	TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2017, 7, 39692.	1.6	35
166	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	3.4	28
167	HER2 Transmembrane Domain Mutations: Rare New Target for Non-“Small Cell Lung Cancer Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, 422-424.	0.5	7
168	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1210-1222.	0.5	112
169	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. <i>Journal of Thoracic Oncology</i> , 2017, 12, 208-222.	0.5	1,067
170	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature Genetics</i> , 2017, 49, 1126-1132.	9.4	472
171	Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 195-202.	0.3	43
172	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 334-346.	0.5	113
173	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq1 1 0.784314 rgBT /Overl 1523-1531.	5.1	158
174	Synergy of WEE1 and mTOR Inhibition in Mutant <i>KRAS</i> -Driven Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 6993-7005.	3.2	29
175	Role of the Extracellular Matrix in Tumor Stroma: Barrier or Support?. , 2017, , 77-112.		0
176	Modeling Drug Resistance in PDX Models. <i>Molecular and Translational Medicine</i> , 2017, , 115-126.	0.4	0
177	Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients. <i>Cancer Immunology Research</i> , 2017, 5, 821-829.	1.6	14
178	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1864-1888.	2.5	32
179	A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, e200-e202.	0.5	25
180	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 111, 23-29.	0.9	160

#	ARTICLE	IF	CITATIONS
181	Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. <i>International Journal of Cancer</i> , 2017, 140, 662-673.	2.3	67
182	A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e41-e47.	1.1	4
183	Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 1060-1067.	3.2	44
184	Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes. <i>Molecular Cancer Research</i> , 2017, 15, 3-14.	1.5	98
185	BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2460-2470.	3.2	8
186	Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium. <i>PLoS ONE</i> , 2017, 12, e0185660.	1.1	11
187	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3867-3876.	0.8	343
188	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2018-2027.	0.8	91
189	Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5522-5522.	0.8	6
190	Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. <i>PLoS ONE</i> , 2017, 12, e0177875.	1.1	79
191	Characterizing the last holdouts. <i>Oncotarget</i> , 2017, 8, 12542-12543.	0.8	1
192	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 57528-57536.	0.8	7
193	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. <i>Oncotarget</i> , 2017, 8, 69651-69662.	0.8	23
194	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017, 8, 84659-84670.	0.8	13
195	Abstract A64: Mast cell expressed Fc̳R beta subunit (MS4A2) is prognostic in lung adenocarcinoma. , 2017, , .		0
196	A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 332-332.	0.8	0
197	Patients'™ willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18329-e18329.	0.8	0
198	Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9024-9024.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Use of a marketing plan for recruitment to a lung cancer screening study.. Journal of Clinical Oncology, 2017, 35, 1548-1548.	0.8	0
200	SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis. PLoS Biology, 2016, 14, e1002581.	2.6	35
201	From Solo in the Silo to Strategic Training Programs. CBE Life Sciences Education, 2016, 15, 1e1.	1.1	3
202	Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2016, 11, 312-323.	0.5	50
203	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1267-1272.	1.2	95
204	ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiology, 2016, 41, 50-56.	0.8	7
205	Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. Clinical Lung Cancer, 2016, 17, 375-383.e2.	1.1	12
206	Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients. Lung Cancer, 2016, 92, 53-61.	0.9	86
207	Programmed Death Ligand-1 Immunohistochemistry—A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 341-344.	1.2	107
208	Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 157, 109-116.	1.1	38
209	Anti-PD-1-associated organizing pneumonia in a responding melanoma patient. Annals of Oncology, 2016, 27, 1649-1650.	0.6	13
210	An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib. Journal of Thoracic Oncology, 2016, 11, 2248-2252.	0.5	3
211	A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature, 2016, 538, 378-382.	13.7	418
212	Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1281-1284.	1.2	26
213	Response to Yamamoto et al.. Journal of Thoracic Oncology, 2016, 11, e129-e130.	0.5	0
214	A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. Journal of Clinical Pathology, 2016, 69, 607-611.	1.0	15
215	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine, 2016, 8, 109.	3.6	211
216	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. Journal of Thoracic Oncology, 2016, 11, 850-861.	0.5	78

#	ARTICLE	IF	CITATIONS
217	Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. <i>Chest</i> , 2016, 150, 1015-1022.	0.4	45
218	Computer Vision Tool and Technician as First Reader of Lung Cancer Screening CT Scans. <i>Journal of Thoracic Oncology</i> , 2016, 11, 709-717.	0.5	30
219	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
220	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1223-1230.	0.8	300
221	Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 900-909.	0.5	27
222	Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials. <i>Clinical Cancer Research</i> , 2016, 22, PR03-PR03.	3.2	6
223	Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2016, 34, 11585-11585.	0.8	6
224	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 25632-25639.	0.8	9
225	Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. <i>Oncotarget</i> , 2016, 7, 33571-33580.	0.8	39
226	Taking action on actionable mutations: a French initiative on universality in precision cancer care. <i>Translational Cancer Research</i> , 2016, 5, S35-S39.	0.4	0
227	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. <i>Journal of Thoracic Oncology</i> , 2015, 10, 985-989.	0.5	241
228	Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung. <i>Clinical Cancer Research</i> , 2015, 21, 1477-1486.	3.2	13
229	Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1172-1180.	0.5	33
230	The 2015 World Health Organization Classification of Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1243-1260.	0.5	3,313
231	Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy. , 2015, , .		8
232	Predictive Versus Prognostic Value of Lung Adenocarcinoma Classification. <i>Journal of Clinical Oncology</i> , 2015, 33, 225-226.	0.8	2
233	Plasma pro-surfactant protein B and lung function decline in smokers. <i>European Respiratory Journal</i> , 2015, 45, 1037-1045.	3.1	30
234	Phase II study of PX-866 in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1270-4.	0.6	77

#	ARTICLE	IF	CITATIONS
235	Optimization of miRNA-seq data preprocessing. <i>Briefings in Bioinformatics</i> , 2015, 16, 950-963.	3.2	120
236	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i> -Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2472-2480.	0.8	94
237	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , 2015, 33, 3439-3446.	0.8	234
238	CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration. <i>Molecular Cancer Research</i> , 2015, 13, 1119-1129.	1.5	43
239	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2499-2505.	3.2	48
240	Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 438-445.	1.2	9
241	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. <i>Nature Medicine</i> , 2015, 21, 1364-1371.	15.2	591
242	A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. <i>Cancer Cell</i> , 2015, 28, 623-637.	7.7	68
243	Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. <i>Lung Cancer</i> , 2015, 89, 110-114.	0.9	17
244	Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 11060-11060.	0.8	2
245	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2594-2594.	0.8	4
246	Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7521-7521.	0.8	3
247	Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers. <i>PLoS ONE</i> , 2015, 10, e0121872.	1.1	21
248	Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Disease</i> , 2015, 7, 1898-906.	0.6	17
249	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 67-81.	1.3	241
250	Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19006-e19006.	0.8	0
251	<i>EGFR</i> mutations in NSCLC: Does ethnicity influence outcomes?. <i>Journal of Clinical Oncology</i> , 2015, 33, e17633-e17633.	0.8	0
252	Abstract A102: Combination treatment with hypoxia-activated prodrug TH-302 and radiation reduce pancreatic tumor initiating cells and tumor growth in patient-derived xenografts. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
253	Abstract A106: BRCA mutation sensitizes pancreatic tumors to treatment with cisplatin. , 2015, , .		0
254	Abstract 1822: Proteome signatures distinguish lung cancer subtypes, define metabolism states, and have prognostic impact. , 2015, , .		0
255	Abstract B2-01: Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. , 2015, , .		0
256	Abstract A2-49: Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. , 2015, , .		0
257	p120RasGAP Is a Mediator of Rho Pathway Activation and Tumorigenicity in the DLD1 Colorectal Cancer Cell Line. PLoS ONE, 2014, 9, e86103.	1.1	15
258	Characterization of collagen in non-small cell lung carcinoma with second harmonic polarization microscopy. Biomedical Optics Express, 2014, 5, 3562.	1.5	55
259	National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 11-17.	0.7	11
260	Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nature Communications, 2014, 5, 5469.	5.8	93
261	Preparing for tomorrow: Molecular diagnostics and the changing nonsmall cell lung cancer landscape. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 2-10.	0.7	4
262	Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?. European Respiratory Journal, 2014, 44, 1011-1022.	3.1	63
263	A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The "SMART" Approach for Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2014, 9, 397-402.	0.5	117
264	PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 2014, 9, 239-247.	0.5	30
265	Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1255-1263.	0.5	73
266	Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. Journal of Thoracic Oncology, 2014, 9, 1449-1458.	0.5	45
267	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. Journal of Thoracic Oncology, 2014, 9, 141-143.	0.5	23
268	Forty Years of the International Association for Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2014, 9, 1740-1749.	0.5	6
269	Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. Journal of Thoracic Oncology, 2014, 9, 1354-1362.	0.5	34
270	Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients. Journal of Thoracic Oncology, 2014, 9, 59-64.	0.5	243



#	ARTICLE	IF	CITATIONS
271	Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing. <i>Journal of Thoracic Oncology</i> , 2014, 9, 947-956.	0.5	72
272	Reply to C.G. Azzoli et al and C. Chouaid et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3578-3579.	0.8	1
273	Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts. <i>Cancers</i> , 2014, 6, 459-471.	1.7	57
274	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non-Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. <i>Clinical Lung Cancer</i> , 2014, 15, 52-57.	1.1	32
275	The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. <i>Nature Methods</i> , 2014, 11, 585-592.	9.0	149
276	Proteomic profiles of human lung adenocarcinoma and squamous cell carcinoma using super-SILAC and label-free quantification approaches. <i>Proteomics</i> , 2014, 14, 795-803.	1.3	24
277	Robust global microRNA expression profiling using next-generation sequencing technologies. <i>Laboratory Investigation</i> , 2014, 94, 350-358.	1.7	118
278	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 135, 184-189.	0.6	84
279	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 1379-1388.	5.1	119
280	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014, 35, 1267-1275.	1.3	57
281	Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1012-1019.	0.8	85
282	Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma. <i>Histopathology</i> , 2014, 64, 826-839.	1.6	22
283	The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1. <i>Cancer Cell</i> , 2014, 25, 181-195.	7.7	76
284	A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 84, 289-294.	0.9	11
285	Genes and Pathology of Non-Small Cell Lung Carcinoma. <i>Seminars in Oncology</i> , 2014, 41, 28-39.	0.8	59
286	Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity. <i>Journal of Clinical Oncology</i> , 2014, 32, 6041-6041.	0.8	5
287	A targeted intervention to improve awareness to molecular testing in NSCLC. <i>Journal of Clinical Oncology</i> , 2014, 32, 6547-6547.	0.8	1
288	Lung cancer in never-smokers from the Princess Margaret Cancer Centre. <i>Journal of Clinical Oncology</i> , 2014, 32, 8099-8099.	0.8	1

#	ARTICLE	IF	CITATIONS
289	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience.. Journal of Clinical Oncology, 2014, 32, 459-459.	0.8	1
290	SOX15 and other SOX family members are important mediators of tumorigenesis in multiple cancer types.. Oncoscience, 2014, 1, 326-335.	0.9	46
291	Prognostic markers in lung cancer: is it ready for prime time?. Translational Lung Cancer Research, 2014, 3, 149-58.	1.3	42
292	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
293	Abstract IA10: Molecular testing to personalized EGFR and ALK inhibitor therapies in lung cancer.. Clinical Cancer Research, 2014, 20, IA10-IA10.	3.2	0
294	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Center experience.. Journal of Clinical Oncology, 2014, 32, 3572-3572.	0.8	0
295	Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, 6595-6595.	0.8	0
296	Canadian ALK (CALK): A multicenter, prospective study of concurrent ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in NSCLC.. Journal of Clinical Oncology, 2014, 32, 8070-8070.	0.8	0
297	Abstract 1184: Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patient-derived xenografts (PDX) of non-small cell lung cancer (NSCLC). , 2014, , .		1
298	Abstract 4800: Heterogeneity of cancer associated fibroblasts in non-small cell lung cancer is defined by the level of collagen gel contraction activity. , 2014, , .		0
299	Abstract 1553: Rho guanine nucleotide exchange factor (ARHGEF) 10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. , 2014, , .		0
300	Regulation of pancreatic cancer growth by superoxide. Molecular Carcinogenesis, 2013, 52, 555-567.	1.3	40
301	Probability of Cancer in Pulmonary Nodules Detected on First Screening CT. New England Journal of Medicine, 2013, 369, 910-919.	13.9	1,020
302	<scp>NKG</scp>2<scp>D</scp> regulates production of soluble <scp>TRAIL</scp> by ex vivo expanded human Î³Î³<scp>T</scp> cells. European Journal of Immunology, 2013, 43, 3175-3182.	1.6	45
303	Applications of Array-CGH for Lung Cancer. Methods in Molecular Biology, 2013, 973, 297-324.	0.4	6
304	ERCC1 Isoform Expression and DNA Repair in Non-“Small-Cell Lung Cancer. New England Journal of Medicine, 2013, 368, 1101-1110.	13.9	342
305	Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. Lung Cancer, 2013, 79, 215-220.	0.9	30
306	Molecular Prognostication of Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2013, 25, 4-7.	0.4	2

#	ARTICLE	IF	CITATIONS
307	Long-Term Outcome after En Bloc Resection of Non-Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1538-1544.	0.5	36
308	Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. <i>Laboratory Investigation</i> , 2013, 93, 397-407.	1.7	24
309	In Compressed Lung Tissue Microscopic Sections of Adenocarcinoma In Situ May Mimic Papillary Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1792-1797.	1.2	20
310	Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3320-3326.	0.8	327
311	Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein. <i>Cancer Research</i> , 2013, 73, 1934-1945.	0.4	80
312	Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2173-2181.	0.8	270
313	KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 530-542.	0.5	104
314	Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1371-1377.	0.5	27
315	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67876.	1.1	31
316	Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e71670.	1.1	74
317	Genomic Pathology of Lung Cancer. , 2013, , 1-46.		1
318	Abstract B282: The PLK-4 inhibitor CFI-400945 reduces tumor growth in patient-derived pancreatic xenografts.. , 2013, , .		2
319	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11002-11002.	0.8	16
320	Plasma osteopontin and the prognosis of pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11109-11109.	0.8	1
321	Phase II study of PX-866 in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2053-2053.	0.8	3
322	Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8096-8096.	0.8	2
323	Loss of Canonical Smad4 Signaling Promotes KRAS Driven Malignant Transformation of Human Pancreatic Duct Epithelial Cells and Metastasis. <i>PLoS ONE</i> , 2013, 8, e84366.	1.1	30
324	Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 196-196.	0.8	0

#	ARTICLE	IF	CITATIONS
325	Performance of a prognostic genomic signature for early-stage NSCLC in matched fresh frozen and RNA-stabilized tissue.. Journal of Clinical Oncology, 2013, 31, 7532-7532.	0.8	0
326	Clinical impact of <i>EGFR</i> mutation fraction and tumor cellularity in <i>EGFR</i> mutation positive NSCLC.. Journal of Clinical Oncology, 2013, 31, e19077-e19077.	0.8	0
327	Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study.. Journal of Clinical Oncology, 2013, 31, 7516-7516.	0.8	0
328	ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study.. Journal of Clinical Oncology, 2013, 31, e22042-e22042.	0.8	0
329	Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).. Journal of Clinical Oncology, 2013, 31, 7517-7517.	0.8	0
330	Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2013, 31, 11057-11057.	0.8	1
331	Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, e19032-e19032.	0.8	0
332	Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19031-e19031.	0.8	0
333	Willingness of patients to provide biologic samples for pharmacogenomic testing.. Journal of Clinical Oncology, 2013, 31, 6543-6543.	0.8	1
334	Ancillary Testing in Lung Cancer Diagnosis. Pulmonary Medicine, 2012, 2012, 1-8.	0.5	14
335	L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 1914-1924.	3.2	48
336	Expression of Kallikrein-Related Peptidase 7 Predicts Poor Prognosis in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1135-1142.	1.1	29
337	Association of the 15q25 and 5p15 Lung Cancer Susceptibility Regions with Gene Expression in Lung Tumor Tissue. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1097-1104.	1.1	18
338	A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 963-972.	0.5	33
339	Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. Journal of Thoracic Oncology, 2012, 7, 1653-1660.	0.5	107
340	Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1101-1108.	0.5	44
341	Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 1513-1521.	0.5	46
342	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	0.5	23

#	ARTICLE	IF	CITATIONS
343	Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. <i>Modern Pathology</i> , 2012, 25, 758-766.	2.9	99
344	Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma. <i>New England Journal of Medicine</i> , 2012, 367, 1417-1427.	13.9	255
345	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	0.8	229
346	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.	13.7	1,741
347	Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 235-241.	0.9	29
348	Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: Review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. <i>Lung Cancer</i> , 2012, 77, 501-506.	0.9	41
349	Comprehensive genomic characterization of squamous cell lung cancers. <i>Nature</i> , 2012, 489, 519-525.	13.7	3,483
350	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. <i>Genome Medicine</i> , 2012, 4, 84.	3.6	15
351	Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development. <i>PLoS ONE</i> , 2012, 7, e37775.	1.1	56
352	Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e46677.	1.1	64
353	Abstract 4912: Systematic, comparative network analysis on non-small cell lung cancer. <i>Cancer Research</i> , 2012, 72, 4912-4912.	0.4	1
354	A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1036-1036.	0.8	3
355	Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7007-7007.	0.8	9
356	Abstract A29: Genomic alteration of E2F/Rb activates EZH2 in small cell lung cancer. <i>Clinical Cancer Research</i> , 2012, 18, A29-A29.	3.2	0
357	Abstract B34: Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012, 18, B34-B34.	3.2	0
358	Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 240-240.	0.8	0
359	Abstract 1232: Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. , 2012, , .		0
360	Abstract 5069: Genomic profiles of primary non-small cell lung cancer (NSCLC) xenograft tumors identify distinct gene signatures associated with histological subtypes. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
361	Abstract 5127: Characterization of lung cancers by integrated genomic and proteomic analysis. , 2012, , .		0
362	Abstract 4210: Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. , 2012, , .		0
363	Abstract 4805: Distinctive phospho-proteome signatures in non-small cell lung carcinoma tumors. , 2012, , .		0
364	Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2012, 30, 7586-7586.	0.8	0
365	The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.. Journal of Clinical Oncology, 2012, 30, 10522-10522.	0.8	3
366	Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 1535-1535.	0.8	0
367	Phase II study of PX-866 in recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2051-2051.	0.8	0
368	Primary Tumor Xenografts of Human Lung Adeno and Squamous Cell Carcinoma Express Distinct Proteomic Signatures. Journal of Proteome Research, 2011, 10, 161-174.	1.8	27
369	Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal Cancer. Journal of Proteome Research, 2011, 10, 3200-3211.	1.8	27
370	Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	7.7	455
371	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. Journal of Thoracic Oncology, 2011, 6, 1663-1669.	0.5	37
372	Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1521-1529.	0.5	54
373	A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1379-1391.	0.5	89
374	Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 139-147.	0.5	63
375	EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 49-69.	9.6	644
376	Modified gateway system for double shRNA expression and Cre/lox based gene expression. BMC Biotechnology, 2011, 11, 24.	1.7	10
377	The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck Oncology, 2011, 3, 11.	2.3	75
378	Differential utilization of NF-kappaB RELA and RELB in response to extracellular versus intracellular polyIC stimulation in HT1080 cells. BMC Immunology, 2011, 12, 15.	0.9	9

#	ARTICLE	IF	CITATIONS
379	Genomic and Cellular Pathology of Lung Cancer. <i>Current Respiratory Medicine Reviews</i> , 2011, 7, 313-322.	0.1	1
380	Optimized application of penalized regression methods to diverse genomic data. <i>Bioinformatics</i> , 2011, 27, 3399-3406.	1.8	73
381	Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7160-7165.	3.3	317
382	Global Profiling and Molecular Characterization of Alternative Splicing Events Misregulated in Lung Cancer. <i>Molecular and Cellular Biology</i> , 2011, 31, 138-150.	1.1	149
383	Interaction between <i>MYC</i> and <i>MCL1</i> in the Genesis and Outcome of Non-Small-Cell Lung Cancer. <i>Cancer Research</i> , 2011, 71, 2212-2221.	0.4	39
384	The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 134-141.	3.2	147
385	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 244-285.	0.5	4,127
386	Phase II Study of Temozolomide in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3278-3285.	0.8	321
387	Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus. <i>PLoS Pathogens</i> , 2011, 7, e1002240.	2.1	404
388	TRAF6 is an amplified oncogene bridging the RAS and NF- $\kappa$ B pathways in human lung cancer. <i>Journal of Clinical Investigation</i> , 2011, 121, 4095-4105.	3.9	151
389	Abstract 2431: Inhibition of metastasis through therapeutic targeting of focal adhesion kinase (FAK) in pancreatic cancer. , 2011, , .		0
390	Abstract 5097: Proteomic characterization of non-small cell lung cancer (NSCLC): Discovery and validation of NSCLC protein signatures and signaling networks. , 2011, , .		0
391	Abstract 1404: L1CAM in non-small-cell lung carcinoma. , 2011, , .		0
392	Abstract 4919: Multiplexed EGFR signaling pathway analysis in FFPE tissue using quantitative mass spectrometry. , 2011, , .		0
393	A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 609-613.	0.6	61
394	Fibroblast Growth Factor Inhibitors. <i>Journal of Thoracic Oncology</i> , 2010, 5, S457.	0.5	0
395	Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. <i>BMC Cancer</i> , 2010, 10, 285.	1.1	67
396	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. <i>Cancer</i> , 2010, 116, 5599-5607.	2.0	143

#	ARTICLE	IF	CITATIONS
397	Detection of <i>EGFR</i> and <i>KRAS</i> mutations in fine-needle aspirates stored on Whatman FTA cards. <i>Cancer Cytopathology</i> , 2010, 118, 450-456.	1.4	46
398	A sequence-based approach to identify reference genes for gene expression analysis. <i>BMC Medical Genomics</i> , 2010, 3, 32.	0.7	41
399	HDL-Mimicking Peptide-Lipid Nanoparticles with Improved Tumor Targeting. <i>Small</i> , 2010, 6, 430-437.	5.2	122
400	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010, 463, 899-905.	13.7	3,331
401	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
402	Transcriptome Profiles of Carcinoma-in-Situ and Invasive Non-Small Cell Lung Cancer as Revealed by SAGE. <i>PLoS ONE</i> , 2010, 5, e9162.	1.1	23
403	Epidermal Growth Factor Receptor Biomarkers in Non-Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma. <i>Journal of Clinical Oncology</i> , 2010, 28, 903-905.	0.8	28
404	Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. <i>Journal of Clinical Oncology</i> , 2010, 28, 29-34.	0.8	379
405	Plasma Transforming Growth Factor $\beta$ and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21. <i>Journal of Clinical Oncology</i> , 2010, 28, 5247-5256.	0.8	51
406	Re: Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1677-1678.	3.0	7
407	Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4417-4424.	0.8	405
408	Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma. <i>PLoS Medicine</i> , 2010, 7, e1000315.	3.9	87
409	Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3316-3322.	0.8	96
410	FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. <i>Journal of Clinical Pathology</i> , 2010, 63, 630-634.	1.0	83
411	Prognostic Gene Expression Signature for Squamous Cell Carcinoma of Lung. <i>Clinical Cancer Research</i> , 2010, 16, 5038-5047.	3.2	31
412	Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience. <i>Lung Cancer</i> , 2010, 67, 177-183.	0.9	106
413	Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma. <i>Molecular Cancer</i> , 2010, 9, 24.	7.9	45
414	Adoptive immunotherapy of cancer using ex vivo expanded human $\beta$ 1 T cells: A new approach. <i>Cancer Letters</i> , 2010, 297, 126-136.	3.2	48



#	ARTICLE	IF	CITATIONS
415	Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 298-306.	3.0	64
416	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. <i>Journal of Clinical Investigation</i> , 2010, 120, 3296-3309.	3.9	129
417	Abstract 5566: Phosphoproteomic profiling of Met / K-Ras signaling in colorectal cancer by label-free LTQ-Orbitrap mass spectrometry. , 2010, , .		0
418	Abstract 3133: In vitro modeling of human pancreatic duct epithelial cell transformation. , 2010, , .		0
419	Abstract 1091: The role for retinoblastoma-like p130 (RBL2) and DNA damage response in human pancreatic cancer cells. , 2010, , .		0
420	Abstract 5049: Functional significance of L1CAM in non-small cell lung cancer. , 2010, , .		0
421	Abstract 1998: A sparse prognostic gene signature for stage IB and II patients with completely resected non-small cell lung cancer. , 2010, , .		0
422	Prognostic gene signatures for non-small-cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2824-2828.	3.3	182
423	Absence of Caspase-3 Protects Pancreatic $\beta$ -Cells from c-Myc-induced Apoptosis without Leading to Tumor Formation. <i>Journal of Biological Chemistry</i> , 2009, 284, 10947-10956.	1.6	22
424	TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 797-802.	3.3	113
425	Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor $\beta$ 1 and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer. <i>Cancer Research</i> , 2009, 69, 4517-4526.	0.4	90
426	Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 441-447.e1.	0.4	40
427	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. <i>Nature Genetics</i> , 2009, 41, 1238-1242.	9.4	862
428	Carcinoma-Associated Fibroblasts in Lung Cancer. , 2009, , 193-215.		0
429	A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma. <i>American Journal of Human Genetics</i> , 2009, 85, 679-691.	2.6	489
430	Understanding Prognostic Gene Expression Signatures in Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 331-340.	1.1	59
431	Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 6229-6236.	0.8	93
432	Molecular predictive and prognostic markers in non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2009, 10, 1001-1010.	5.1	194

#	ARTICLE	IF	CITATIONS
433	Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells. <i>Neoplasia</i> , 2009, 11, 1292-1N6.	2.3	61
434	Gene Expression Profiling of Adenosine Triphosphate-Binding Cassette Transporters in Response to K-ras Activation and Hypoxia in Human Pancreatic Cancer Cell Cultures. <i>Pancreas</i> , 2009, 38, 85-93.	0.5	4
435	Defining Genomic Alteration Boundaries for a Combined Small Cell and Non-small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 227-239.	0.5	18
436	Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma—Epigenetic downregulation of caspases. <i>International Journal of Cancer</i> , 2008, 123, 1751-1760.	2.3	64
437	Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. <i>Modern Pathology</i> , 2008, 21, 817-825.	2.9	97
438	Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. <i>Modern Pathology</i> , 2008, 21, 271-281.	2.9	58
439	Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008, 14, 822-827.	15.2	1,015
440	Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice. <i>Gynecologic Oncology</i> , 2008, 108, 395-401.	0.6	12
441	Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. <i>BMC Cancer</i> , 2008, 8, 43.	1.1	52
442	Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 823-829.	0.4	136
443	Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , 2008, 26, 4268-4275.	0.8	674
444	TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. <i>Genes and Development</i> , 2008, 22, 2677-2691.	2.7	378
445	Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10155-10160.	3.3	64
446	Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. <i>Carcinogenesis</i> , 2008, 29, 647-655.	1.3	53
447	Human Pancreatic Duct Epithelial Cell Model for KRAS Transformation. <i>Methods in Enzymology</i> , 2008, 439, 1-13.	0.4	34
448	Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 527-529.	0.5	63
449	Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients. <i>Personalized Medicine</i> , 2008, 5, 325-329.	0.8	0
450	Keratinocyte Growth Factor/Fibroblast Growth Factor-7-regulated Cell Migration and Invasion through Activation of NF- $\kappa$ B Transcription Factors. <i>Journal of Biological Chemistry</i> , 2007, 282, 6001-6011.	1.6	86

#	ARTICLE	IF	CITATIONS
451	Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5240-5247.	0.8	304
452	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984.	0.8	240
453	Abelson Interactor Protein-1 Positively Regulates Breast Cancer Cell Proliferation, Migration, and Invasion. <i>Molecular Cancer Research</i> , 2007, 5, 1031-1039.	1.5	44
454	Integrin $\alpha$ 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 11754-11759.	3.3	141
455	Three-Gene Prognostic Classifier for Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5562-5569.	0.8	226
456	Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap?. <i>Journal of the National Cancer Institute</i> , 2007, 99, 826-827.	3.0	4
457	Class III $\beta$ -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10. <i>Clinical Cancer Research</i> , 2007, 13, 994-999.	3.2	138
458	KIF14 Messenger RNA Expression Is Independently Prognostic for Outcome in Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3229-3234.	3.2	92
459	Should Mutational Analyses of Tumor Samples Bypass Histopathology?. <i>Journal of Thoracic Oncology</i> , 2007, 2, 375-376.	0.5	5
460	Dissociation of Gemcitabine Sensitivity and Protein Kinase B Signaling in Pancreatic Ductal Adenocarcinoma Models. <i>Pancreas</i> , 2007, 35, e16-e26.	0.5	13
461	Quantitative image analysis of immunohistochemical stains using a CMYK color model. <i>Diagnostic Pathology</i> , 2007, 2, 8.	0.9	148
462	Cigarette smoke components inhibited intercellular communication and differentiation in human pancreatic ductal epithelial cells. <i>International Journal of Cancer</i> , 2007, 120, 1855-1862.	2.3	27
463	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007, 450, 893-898.	13.7	1,020
464	UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium. <i>Gynecologic Oncology</i> , 2007, 106, 305-310.	0.6	67
465	A6-06: Integrative genomic and gene expression analysis of NSCLC identifies subtype-specific signatures of pathway disruption. <i>Journal of Thoracic Oncology</i> , 2007, 2, S328.	0.5	0
466	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations. <i>Clinical Lung Cancer</i> , 2006, 7, S138-S144.	1.1	76
467	A review of erlotinib and its clinical use. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 177-193.	0.9	74
468	C/EBP $\beta$ mutations in lung cancer. <i>Lung Cancer</i> , 2006, 53, 253-254.	0.9	15

#	ARTICLE	IF	CITATIONS
469	Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. <i>Human Pathology</i> , 2006, 37, 212-217.	1.1	47
470	Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefits in an Orthotopic Human Non-small Cell Lung Cancer Model. <i>Journal of Thoracic Oncology</i> , 2006, 1, 771-779.	0.5	18
471	Ethanol and the Tobacco-specific Carcinogen, NNK, Contribute to Signaling in Immortalized Human Pancreatic Duct Epithelial Cells. <i>Pancreas</i> , 2006, 33, 53-62.	0.5	31
472	Identification of Novel Lung Genes in Bronchial Epithelium by Serial Analysis of Gene Expression. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 35, 651-661.	1.4	51
473	K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. <i>Clinical Lung Cancer</i> , 2006, 8, 30-38.	1.1	212
474	Large fragment Bst DNA polymerase for whole genome amplification of DNA from formalin-fixed paraffin-embedded tissues. <i>BMC Genomics</i> , 2006, 7, 312.	1.2	37
475	Grg1 Acts as a Lung-Specific Oncogene in a Transgenic Mouse Model. <i>Cancer Research</i> , 2006, 66, 1294-1301.	0.4	49
476	Genomic DNA functions as a universal external standard in quantitative real-time PCR. <i>Nucleic Acids Research</i> , 2006, 34, e85-e85.	6.5	137
477	Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1219-1220.	0.8	107
478	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. <i>Journal of Thoracic Oncology</i> , 2006, 1, S13-S19.	0.5	106
479	Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. <i>Oncogene</i> , 2005, 24, 4806-4812.	2.6	60
480	DJ-1, a novel regulator of the tumor suppressor PTEN. <i>Cancer Cell</i> , 2005, 7, 263-273.	7.7	495
481	High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 308-313.	1.5	44
482	Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. <i>Molecular Carcinogenesis</i> , 2005, 43, 215-224.	1.3	75
483	The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through $\beta^2$ -adrenergic transactivation of EGF receptors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 639-648.	1.2	92
484	In vitro Modeling of Human Pancreatic Duct Epithelial Cell Transformation Defines Gene Expression Changes Induced by K-ras Oncogenic Activation in Pancreatic Carcinogenesis. <i>Cancer Research</i> , 2005, 65, 5045-5053.	0.4	110
485	A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5526-5533.	3.2	99
486	The Association of Measured Breast Tissue Characteristics with Mammographic Density and Other Risk Factors for Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 343-349.	1.1	283

#	ARTICLE	IF	CITATIONS
487	KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. <i>Oncogene</i> , 2005, 24, 4741-4753.	2.6	167
488	Erlotinib in Lung Cancer – Molecular and Clinical Predictors of Outcome. <i>New England Journal of Medicine</i> , 2005, 353, 133-144.	13.9	1,787
489	Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3279-3287.	0.8	264
490	Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 2589-2597.	13.9	1,737
491	Epithelial-Cadherin and $\beta$ -Catenin Expression Changes in Pancreatic Intraepithelial Neoplasia. <i>Clinical Cancer Research</i> , 2004, 10, 1235-1240.	3.2	101
492	Overexpression of G1-S Cyclins and Cyclin-Dependent Kinases during Multistage Human Pancreatic Duct Cell Carcinogenesis. <i>Clinical Cancer Research</i> , 2004, 10, 6598-6605.	3.2	39
493	Expression of Chicken Ovalbumin Upstream Promoter-Transcription Factor II Enhances Invasiveness of Human Lung Carcinoma Cells. <i>Cancer Research</i> , 2004, 64, 5097-5105.	0.4	38
494	Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker. <i>Clinical Cancer Research</i> , 2004, 10, 1984-1991.	3.2	79
495	grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten <sup>+/-</sup> mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15358-15363.	3.3	16
496	Brca2 Deficiency Does Not Impair Mammary Epithelium Development but Promotes Mammary Adenocarcinoma Formation in p53 <sup>+/-</sup> Mutant Mice. <i>Cancer Research</i> , 2004, 64, 1959-1965.	0.4	42
497	Identification of 27 CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. <i>Oncogene</i> , 2004, 23, 8705-8710.	2.6	115
498	Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. <i>Oncogene</i> , 2004, 23, 6316-6324.	2.6	31
499	Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. <i>Lung Cancer</i> , 2004, 46, 197-204.	0.9	43
500	Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1725-1730.	3.3	150
501	Stability and Heterogeneity of Expression Profiles in Lung Cancer Specimens Harvested Following Surgical Resection. <i>Neoplasia</i> , 2004, 6, 761-767.	2.3	43
502	Dysregulated PTEN-PKB and negative receptor status in human breast cancer. <i>International Journal of Cancer</i> , 2003, 104, 195-203.	2.3	78
503	Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. <i>Lung Cancer</i> , 2003, 41, 91-99.	0.9	19
504	High Expression of Met/Hepatocyte Growth Factor Receptor Suppresses Tumorigenicity in NCI-H1264 Lung Carcinoma Cells. <i>Experimental Cell Research</i> , 2002, 273, 45-53.	1.2	7

#	ARTICLE	IF	CITATIONS
505	Peptide differential display of serum-free conditioned medium from cancer cell lines. <i>Cancer Letters</i> , 2002, 176, 199-203.	3.2	9
506	The function of multiple I $\kappa$ B $\beta$ :NF- $\kappa$ B complexes in the resistance of cancer cells to Taxol-induced apoptosis. <i>Oncogene</i> , 2002, 21, 6510-6519.	2.6	166
507	Novel candidate tumor marker genes for lung adenocarcinoma. <i>Oncogene</i> , 2002, 21, 7598-7604.	2.6	89
508	Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. <i>Cancer Research</i> , 2002, 62, 3005-8.	0.4	183
509	Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. <i>Cancer Research</i> , 2002, 62, 6194-204.	0.4	38
510	Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. <i>Human Pathology</i> , 2001, 32, 57-65.	1.1	48
511	Primary Pulmonary Primitive Neuroectodermal Tumor (PNET). <i>Pathology Research and Practice</i> , 2001, 197, 121-122.	1.0	0
512	Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. <i>Nature Genetics</i> , 2001, 29, 396-403.	9.4	451
513	Expression of Active Protein Kinase B in T Cells Perturbs Both T and B Cell Homeostasis and Promotes Inflammation. <i>Journal of Immunology</i> , 2001, 167, 42-48.	0.4	80
514	Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. , 2000, 190, 150-156.		107
515	Requirement for glycogen synthase kinase-3 $\beta$ in cell survival and NF- $\kappa$ B activation. <i>Nature</i> , 2000, 406, 86-90.	13.7	1,346
516	Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype. <i>American Journal of Pathology</i> , 2000, 157, 1623-1631.	1.9	287
517	A Study of Smoking, p53 Tumor Suppressor Gene Alterations and Non-Small Cell Lung Cancer. <i>Annals of Epidemiology</i> , 2000, 10, 176-185.	0.9	21
518	Co-expression of epidermal growth factor receptor and transforming growth factor- $\beta$ is independent of ras mutations in lung adenocarcinoma. <i>Lung Cancer</i> , 2000, 29, 151-157.	0.9	59
519	Activation of Hepatocyte Growth Factor-Met Autocrine Loop Enhances Tumorigenicity in a Human Lung Adenocarcinoma Cell Line. <i>Neoplasia</i> , 2000, 2, 226-234.	2.3	52
520	Autotaxin Expression in Non-small-Cell Lung Cancer. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 21, 216-222.	1.4	109
521	Tight junction protein zo-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. , 1999, 82, 137-144.		55
522	zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. , 1999, 83, 349-358.		28

#	ARTICLE	IF	CITATIONS
523	zo2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. International Journal of Cancer, 1999, 83, 349-358.	2.3	1
524	Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer, 1998, 20, 1-16.	0.9	111
525	Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma. American Journal of Pathology, 1998, 153, 263-269.	1.9	131
526	ras mutation and expression of theras-regulated genes osteopontin and cathepsin L in human esophageal cancer. , 1997, 72, 739-745.		69
527	Autocrine Growth Loop of The Epidermal Growth Factor Receptor in Normal and Immortalized Human Bronchial Epithelial Cells. Experimental Cell Research, 1996, 223, 268-273.	1.2	43
528	Malignant rhabdoid tumor of the colon. Diseases of the Colon and Rectum, 1996, 39, 1322-1326.	0.7	40
529	Characterization of Human Bronchial Epithelial Cells Immortalized by the E6 and E7 Genes of Human Papillomavirus Type 16. Experimental Cell Research, 1994, 212, 36-41.	1.2	49
530	Enhanced Expression of Alpha-Fetoprotein Gene in Cultured Rat Liver Epithelial Cells Treated with N-Methyl-N&rsquo;-Nitro-N-Nitrosoguanidine. Pathobiology, 1993, 61, 25-30.	1.9	1
531	Annulate Lamellae in a Large Cell Lung Carcinoma Cell Line with High Expression of Tyrosine Kinase Receptor and Proto-Oncogenes. Ultrastructural Pathology, 1992, 16, 439-449.	0.4	13
532	Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma. American Journal of Surgical Pathology, 1992, 16, 259-268.	2.1	144
533	p53 gene mutations in human endometrial carcinoma. Molecular Carcinogenesis, 1992, 5, 250-253.	1.3	76
534	Expression of protein disulfide isomerase in cultured rat liver epithelial cells is unrelated to the growth inhibitory effect of TGF- $\beta$ 1. Biochemical and Biophysical Research Communications, 1991, 174, 478-482.	1.0	1
535	Regulation by epidermal growth factor of the expression of transforming growth factor- $\beta$ 1 mRNA in cultured rat liver epithelial cells. Experimental Cell Research, 1991, 195, 214-217.	1.2	7
536	Primary pulmonary adenocarcinoma with enteric differentiation. Cancer, 1991, 68, 1754-1757.	2.0	75
537	Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice. Cancer Immunology, Immunotherapy, 1991, 33, 85-90.	2.0	15
538	Effect of proliferative state on glutathione S-transferase isoenzyme in cultured rat liver epithelial cells. Carcinogenesis, 1991, 12, 2031-2034.	1.3	9
539	Genotoxicity of pancreatic chemical carcinogens to propagable cultured normal pancreatic epithelial cells. Experimental and Molecular Pathology, 1990, 53, 203-210.	0.9	4
540	Sequential Changes in Epidermal Growth Factor Receptor/Ligand Function in Cultured Rat Liver Epithelial Cells Transformed Chemically in vitro. Pathobiology, 1990, 58, 3-14.	1.9	20

#	ARTICLE	IF	CITATIONS
541	Hepatic Sinusoidal Fibrosis in Agnogenic Myeloid Metaplasia. American Journal of Clinical Pathology, 1989, 91, 302-305.	0.4	15
542	Glutathione and glutathione S-transferases in clones of cultured rat liver epithelial cells that express varying activity of $\gamma$ -glutamyl transpeptidase. Molecular Carcinogenesis, 1989, 2, 144-149.	1.3	9
543	Activation of murine kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. Hepatology, 1988, 8, 1046-1050.	3.6	39
544	Induction of gamma-glutamyl transpeptidase activity by all-trans retinoic acid in cultured rat liver epithelial cells. Biochemical and Biophysical Research Communications, 1988, 157, 1039-1045.	1.0	6
545	Human Papillomavirus-11 DNA in a Patient with Chronic Laryngotracheobronchial Papillomatosis and Metastatic Squamous-Cell Carcinoma of the Lung. New England Journal of Medicine, 1987, 317, 873-878.	13.9	151
546	Inconsistent effects of all-trans retinoic acid on different clones of chemically transformed rat liver epithelial cells. Carcinogenesis, 1987, 8, 497-501.	1.3	5
547	Establishment of propagable epithelial cell lines from normal adult rat pancreas. Experimental Cell Research, 1987, 168, 365-375.	1.2	37
548	Regulation of growth of cultured hepatic epithelial cells by transferrin. Experimental Cell Research, 1987, 171, 52-62.	1.2	27
549	Inhibition of proliferation of cultured rat liver epithelial cells at specific cell cycle stages by transforming growth factor- $\beta$ . Biochemical and Biophysical Research Communications, 1987, 143, 26-30.	1.0	46
550	The effects of epidermal growth factor and the state of confluence on enzymatic activities of cultured rat liver epithelial cells. Journal of Cellular Physiology, 1986, 126, 167-173.	2.0	28
551	SHORT COMMUNICATION. Carcinogenesis, 1986, 7, 669-671.	1.3	19
552	The modulation of growth of normal rat liver epithelial cells in calcium-poor medium by epidermal growth factor, phenobarbital, phorbol ester, and retinoic acid. In Vitro, 1985, 21, 249-253.	1.2	7
553	Biochemical effects of 12-O-tetradecanoylphorbol-13-acetate, retinoic acid, phenobarbital, and 5-azacytidine on a normal rat liver epithelial cell line. Journal of Cellular Physiology, 1984, 121, 1-6.	2.0	9
554	Cauda Equina Paraganglioma. Canadian Journal of Neurological Sciences, 1983, 10, 266-269.	0.3	11
555	Pathogenesis of pulmonary infarction. American Journal of Medicine, 1982, 72, 599-606.	0.6	85
556	Expression profiling by microarrays in colorectal cancer (Review). Oncology Reports, 0, , .	1.2	22